bottom line report ep well cs/ consensu
estim despit total revenu
essenti in-lin cs/consensu ep beat
larg driven lower-than-expect spend better-
than-expect gross margin interestingli compani also
withdrawn fda file opdivo yervoy non-smal cell lung
cancer patient think approv file
would made much near-term commerci impact anyway
rais new question compani overal strategi approach
commentari guidanc confirm non-gaap ep guidanc
midpoint cs
consensu first time revenu guidanc mid-singl digit
growth also littl cs consensu potenti
due impact currenc fluctuat
notabl point quarter product opdivo yervoy eliqui
modestli lighter consensu sale gap mostli
off-set better-than-consensu perform orencia sprycel
confer call detail move et formerli
et dial us intern passcod
expect call focu insight decis
pull tmb high file nsclc updat
expect around upcom data part part
commerci perform opdivo /- yervoy across tumor type
face greater competit keytruda detail
decis make around acquir celg expect celg
base busi key pipelin asset
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
us million unless otherwis state
sale
net incom
mid-singl digit mid-singl digit
mid-singl digit
high-singl digit
mid-singl digit
high-singl digit
compani mention price
